R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Precision medicine is finding success in cancer care, but not much elsewhere. The reasons why are often more economic than scientific.

R&D

Advancements in medical AI now allow pharmaceutical companies to leverage unstructured clinical data at scale.

R&D

Epilepsy affects women differently than men, owing to the complexity of brain health and the historical lack of investment in women’s health.

R&D

Former surgeon and investment banker Ali Pashazadeh, CEO of Treehill, discusses the current ‘perfect storm’ in biotech.

R&D

Artificial Intelligence (AI) is at the heart of the latest global transformation, not least within the biopharmaceutical industry.

R&D

Hilary Eaton, a rare disease advocate and chief business officer at Profluent, discusses AI-first protein design and accelerating biomedicine.